“We feel that the biotech industry is going through the toughest time now. Everyone knows this, we are having so much difficulty...many investors seem to have stopped investment in the sector,” say Byoung Chul Lee, CEO of the South Korean bioventure Kanaph Therapeutics Inc.
As the pandemic comes to an end, some vigor has returned to major biopharma events like the Bio Korea International Convention, held in Seoul in May, which had thousands of visitors